Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options

Abstract

(1) Background: Spiradenocarcinoma is an extremely rare malignant adnexal tumor and there are only few studies on survival outcomes. Our aim was to perform an analysis of the demographic and pathological characteristics, treatment patterns, and survival outcomes of patients affected by spiradenocarcinoma. (2) Methods: The Surveillance, Epidemiology, and End Results program database of the National Cancer Institute was searched for all cases of spiradenocarcinoma diagnosed between 2000 and 2019. This database is considered representative of the US population. Demographic, pathological, and treatment variables were retrieved. Overall and disease-specific survival were computed according to the different variables. (3) Results: 90 cases of spiradenocarcinoma (47 females, 43 males) were identified. Mean age at diagnosis was 62.8 years. Regional and distant disease at diagnosis were rare, occurring in 2.2% and 3.3% of cases, respectively. Surgery alone was the most frequent treatment (87.8%), followed by a combination of surgery and radiotherapy (3.3%) and radiation therapy only (1.1%). Five-year overall survival was 76.2% and five-year disease-specific survival was 95.7%. (4) Conclusions: Spiradenocarcinoma equally affects males and females. Regional and distant invasion rates are low. Disease-specific mortality is low and is probably overestimated in the literature. Surgical excision remains the main form of treatment.

A malignant spiradenoma of the forehead: a case report and literature review

“…It is more common in the older population, with a median age at diagnosis of 63 years, and without a predilection for any specific gender. It could be associated with the autosomal dominant Brooke-Spielger syndrome [ 6 ]. The tumor would classically present as an abrupt growth of a long-standing indolent, painless nodule.…”

“…Routine lymph node dissection is uncertain, but excision is recommended in cases of positive lymph nodes. Overall, a multidisciplinary approach is very important for accurate diagnosis and management of MSA [ 5 , 6 , 8 , 13 ]. For follow-up, regular assessments are recommended at 3-month intervals in the first year, followed by semiannual checks in the second year and annual evaluations for the subsequent two years.…”

“…MSA usually occurs in patients older than 50 with an average of 59 years [ 5 ]. There have been more than 90 reported cases in the literature, nevertheless MSA remains an extremely rare tumor [ 6 ]. Surgical excision is the usual recommended management for MSA.…”